|
ATCC
pc3 cat crl 1435 cell lines ![]() Pc3 Cat Crl 1435 Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/cell+line+pc-3/pmc13156571-337-13-22?v=ATCC Average 99 stars, based on 1 article reviews
pc3 cat crl 1435 cell lines - by Bioz Stars,
2026-06
99/100 stars
|
Buy from Supplier |
|
ATCC
cell lines vcap atcc cat ![]() Cell Lines Vcap Atcc Cat, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/cell+line+pc-3/pm42120493-409-145-148?v=ATCC Average 99 stars, based on 1 article reviews
cell lines vcap atcc cat - by Bioz Stars,
2026-06
99/100 stars
|
Buy from Supplier |
|
ATCC
human prostate cancer cell line pc 3 ![]() Human Prostate Cancer Cell Line Pc 3, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/cell+line+pc-3/pm42119785-208-1-19?v=ATCC Average 99 stars, based on 1 article reviews
human prostate cancer cell line pc 3 - by Bioz Stars,
2026-06
99/100 stars
|
Buy from Supplier |
|
ATCC
pc3 cell lines ![]() Pc3 Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/cell+line+pc-3/bio_rxiv__64898__2026__04__30__721814-121-2-8?v=ATCC Average 99 stars, based on 1 article reviews
pc3 cell lines - by Bioz Stars,
2026-06
99/100 stars
|
Buy from Supplier |
|
ATCC
human prostate cancer cell lines pc 3 ![]() Human Prostate Cancer Cell Lines Pc 3, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/cell+line+pc-3/pm42042073-83-0-12?v=ATCC Average 99 stars, based on 1 article reviews
human prostate cancer cell lines pc 3 - by Bioz Stars,
2026-06
99/100 stars
|
Buy from Supplier |
|
ATCC
human pc3 metastatic pca cell line ![]() Human Pc3 Metastatic Pca Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/cell+line+pc-3/pmc13106976-56-0-7?v=ATCC Average 99 stars, based on 1 article reviews
human pc3 metastatic pca cell line - by Bioz Stars,
2026-06
99/100 stars
|
Buy from Supplier |
|
ATCC
pc 3 cell line ![]() Pc 3 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/cell+line+pc-3/10__3389_slash_fmolb__2026__1730948-135-18-26?v=ATCC Average 99 stars, based on 1 article reviews
pc 3 cell line - by Bioz Stars,
2026-06
99/100 stars
|
Buy from Supplier |
|
ATCC
culture conditions human prostate cancer cell lines pc 3 ![]() Culture Conditions Human Prostate Cancer Cell Lines Pc 3, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/cell+line+pc-3/pm41986660-58-4-26?v=ATCC Average 99 stars, based on 1 article reviews
culture conditions human prostate cancer cell lines pc 3 - by Bioz Stars,
2026-06
99/100 stars
|
Buy from Supplier |
Journal: iScience
Article Title: The YAP1-NPM1 nuclear complex regulates MYC and reveals a targetable oncogenic node
doi: 10.1016/j.isci.2026.115588
Figure Lengend Snippet: Native NPM1 and YAP1 proteins form complexes in prostate cancer cell models (A) The Venn diagram illustrates proteins associated with YAP1 in LNCaP cells treated with dihydrotestosterone (DHT, 10 nM) or enzalutamide (ENZ, 20 μM) under dextran-coated charcoal-stripped (DCC) serum conditions. Unique and shared proteins for each treatment are indicated. (B) A protein interaction network generated using the GeneMania web portal positions NPM1 within the YAP1 network. (C) Western blot analysis of NPM1 protein levels in AR-positive (LNCaP, C4-2, C4-2B, and 22Rv1) and AR-negative (PC3 and ARCaP) cell lines . β-actin served as a loading control. (D) Quantitative PCR analysis showing correlation between NPM1 transcript and protein levels across the same cell lines. (E) Co-immunofluorescence staining of NPM1 (green) and YAP1 (red) in LNCaP and PC3 cells; nuclei were counterstained with DAPI (blue). Scale bar: 10 μm. (F) Western blot showing NPM1 in YAP1 immune complexes in nuclear extracts from LNCaP, C4-2, C4-2B, and PC3 cells. IgG served as a negative control . (G) Reciprocal co-IP using an NPM1 antibody demonstrates YAP1 presence in NPM1 immune complexes exclusively in PC3 cells. β-actin was used as a loading control. (H) Representative confocal images showing PLA foci (red) indicating YAP1-NPM1 interactions in LNCaP, C4-2, and PC3 cells; nuclei were counterstained with DAPI (blue). Scale bar: 10 μm. (I) Enlarged images of boxed regions from panel H highlight nuclear localization of PLA foci. (J) Quantification of PLA foci per cell across the indicated cell lines. Statistical significance was determined using a two-tailed t test (∗ p < 0.01). Data are represented as mean ± SEM.
Article Snippet: LNCaP (Cat# CRL-1740), C4-2 (Cat# CRL-3314), C4-2B (Cat# CRL-3315), 22Rv1 (Cat# CRL-2505), and
Techniques: Generated, Western Blot, Control, Real-time Polymerase Chain Reaction, Immunofluorescence, Staining, Negative Control, Co-Immunoprecipitation Assay, Two Tailed Test
Journal: iScience
Article Title: The YAP1-NPM1 nuclear complex regulates MYC and reveals a targetable oncogenic node
doi: 10.1016/j.isci.2026.115588
Figure Lengend Snippet: NPM1 influences YAP1 activity and the regulation of its target genes in cellular contexts (A–C) Quantitative PCR analysis of NPM1, YAP1, and MYC mRNA levels in LNCaP and PC3 cells after transient transfection with scrambled or NPM1-specific siRNA. (D and E) Western blot analysis showing YAP1 and MYC protein levels in LNCaP and PC3 cells with or without NPM1 knockdown. (F–G) Quantitative PCR analysis of YAP1 target gene expression in LNCaP and PC3 cells transfected with scramble control or NPM1-specific siRNA (∗ p < 0.001; ∗∗ p < 0.01). Data are represented as mean ± SEM. (I–K) Quantitative PCR analysis of YAP1 target genes (CCN1, CCN2, and ANKRD1) in LNCaP cells after transfection with scramble control or NPM1-specific siRNA, followed by overnight treatment with EtOH (vehicle) or DHT under 5% CSS-fed conditions . Statistical significance was assessed using a two-tailed t test (∗ p < 0.05; ∗∗ p < 0.01). Data are presented as mean ± SEM.
Article Snippet: LNCaP (Cat# CRL-1740), C4-2 (Cat# CRL-3314), C4-2B (Cat# CRL-3315), 22Rv1 (Cat# CRL-2505), and
Techniques: Activity Assay, Real-time Polymerase Chain Reaction, Transfection, Western Blot, Knockdown, Targeted Gene Expression, Control, Two Tailed Test
Journal: iScience
Article Title: The YAP1-NPM1 nuclear complex regulates MYC and reveals a targetable oncogenic node
doi: 10.1016/j.isci.2026.115588
Figure Lengend Snippet: Synergistic interactions between NPM1 and YAP1 regulate cell growth (A) Western blot analysis of NPM1 protein levels in LNCaP cells with or without NPM1 silencing by siRNA; β-actin served as a loading control. (B) Colony-forming ability of LNCaP cells with or without NPM1 knockdown, visualized by crystal violet staining. The accompanying graph presents quantification of colony numbers (∗ p < 0.01, two-tailed t test). (C and D) Dose-response curves for LNCaP, C4-2, C4-2B, and PC3 cells treated with NPM1 inhibitors NSC348884 or nucleozin. Graphs show log values of drug concentration versus percent cell growth; IC50 values were calculated for each cell line. (E–G) Cell-cycle distribution in LNCaP, C4-2, and PC3 cells treated with DMSO (mock), NSC348884, or nucleozin, as evaluated by flow cytometry. Graphs display the percentages of cells in the G1, S, and G2/M phases. (H) Confocal images showing YAP1–NPM1 interactions in LNCaP cells treated with DMSO, NSC348884, or nucleozin under serum-fed conditions. PLA was used to detect YAP1-NPM1 interactions (red foci); nuclei were counterstained with DAPI (blue). Scale bar: 10 μm. The accompanying graph quantifies PLA foci. (I) Cell growth with or without YAP1 induction under NPM1 knockdown conditions, assessed by CCK-8 assay at 72 h post-transfection (∗ p < 0.001; ∗∗ p < 0.01, two-tailed t test). Data are presented as mean ± SEM. (I) Cell growth with or without YAP1 induction under NPM1 knockdown conditions, assessed by CCK-8 assay at 72 h post-transfection (∗ p < 0.001; ∗∗ p < 0.01, two-tailed t test). Data are represented as mean ± SEM.
Article Snippet: LNCaP (Cat# CRL-1740), C4-2 (Cat# CRL-3314), C4-2B (Cat# CRL-3315), 22Rv1 (Cat# CRL-2505), and
Techniques: Western Blot, Control, Knockdown, Staining, Two Tailed Test, Concentration Assay, Flow Cytometry, CCK-8 Assay, Transfection
Journal: iScience
Article Title: The YAP1-NPM1 nuclear complex regulates MYC and reveals a targetable oncogenic node
doi: 10.1016/j.isci.2026.115588
Figure Lengend Snippet: NPM1 regulates cell migration and shows increased interaction with YAP1 in high-grade prostate cancer tissues (A) Wound-healing assay images demonstrate a time-dependent delay in wound closure in LNCaP cells following NPM1 knockdown compared to scramble (Scram) siRNA control ( p < 1.14E−13). Scale bar: 10 μm. (B and C) Migration assays in LNCaP and PC3 cells show reduced motility upon NPM1 depletion in collagen-coated Boyden chambers, with or without EGF stimulation (∗ p < 0.01). Scale bar: 10 μm. Data are from two independent experiments performed in duplicate. (D) Representative PLA micrographs reveal increased YAP1-NPM1 interaction in high-grade tumors (GS > 7) versus low-grade (GS < 7) prostate cancer tissues ( n = 8). Scale bars: 10 and 5 μm, respectively. (E) Quantification of PLA foci in red (corresponding to D) ( n = 8). Data are expressed as mean ± SEM. (F) Schematic summary of findings created using BioRender.
Article Snippet: LNCaP (Cat# CRL-1740), C4-2 (Cat# CRL-3314), C4-2B (Cat# CRL-3315), 22Rv1 (Cat# CRL-2505), and
Techniques: Migration, Wound Healing Assay, Knockdown, Control
Journal: bioRxiv
Article Title: Automated Multimodal Correlative Registration for Organelle-Specific Molecular Imaging
doi: 10.64898/2026.04.30.721814
Figure Lengend Snippet: Subcellular visualization of [ 15 N]B12-PE38 in PC3 cells 6 h post-treatment ( a ) and in tumor ( b ), liver ( c ), and kidney ( d ) 24 h after administration. From left to right: EM image; 15 N/ 14 N and 32 S overlay image; 32 S and EM overlay; 15 N/ 14 N and EM overlay; two representative Zoom-in regions from ¹⁵N/ 14 N and EM overlays showing organelle-level distributions of B12-PE38.
Article Snippet: HeLa and
Techniques:
Journal: Cell Reports Methods
Article Title: Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-loss
doi: 10.1016/j.crmeth.2026.101370
Figure Lengend Snippet: The PDPK1/AKT/FLT DPI and tenovin-6 (T6) show high anti-cancer efficacy in murine tumoroids and human PCa cell lines (A) Dose-response curves for DPI (top) and T6 (bottom) for in vivo and in vitro Pten KO (left), Pten/Stat3 KO (middle), and Pten/Tp53 KO (right) tumoroids. Points represent means of technical duplicates per tumoroid line ( N = 3). Curve fitting was performed using GraphPad Prism 8.0.2. (B) Bar graphs showing means and ±SD of half-maximal inhibitory concentration (IC50) for DPI (top) and T6 (bottom) for in vivo and in vitro tumoroid lines of all genotypes ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA, Tukey’s test). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05. (C) Bar graphs depicting means and ±SD of IC50 values of DPI (left) and T6 (right) on human PCa cell lines. 22RV1: primary PCa; LNCaP: metastatic PCa; DU145, PC3: metastatic castration-resistant PCa ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05; ∗∗ p ≤ 0.01. (D) Heatmaps of synergy scores calculated with the highest single agent (HSA) model for DPI and enzalutamide (left), and T6 and enzalutamide (right) on the human LNCaP cell line. Values > 0 represent synergistic effects, and values < 0 represent antagonistic effects. IC50 concentrations of respective compounds are underlined ( N = 3). See also .
Article Snippet:
Techniques: In Vivo, In Vitro, Concentration Assay